Mesenchymal stem cell

Stem Cell Therapy Global Market Report 2022: Increasing Expansion of Facilities by Market Players Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Health, Stem Cells, Autoimmunity, Growth, Region, AstraZeneca, Embryonic stem cell, Stem cell, Microsoft, Health, Immune system, ATMP, Parkinson's disease, University, Cell, Tissue, COPD, Therapy, Regenerative medicine, Lupus, B-cell lymphoma, Degenerative disease, Inflammation, Mesenchymal stem cell, Centre for Regenerative Medicine, Multiple myeloma, Injury, ALS, Behavior, Research, SSCS, Focus, Focus group, Multiple sclerosis, Quality of life, Stem, Application, NSCS, Crohn's disease, B cell, National Center for Regenerative Medicine, Vaccine, Pharmaceutical industry

There are four types of Adipose-derived stem cells therapy hematopoietic stem cells (HSCs), skin stem cells (SSCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs).

Key Points: 
  • There are four types of Adipose-derived stem cells therapy hematopoietic stem cells (HSCs), skin stem cells (SSCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs).
  • Increasing expansion of facilities by market players for stem cell therapies is expected to propel growth of the stem cell therapy market over the forecast period.
  • Furthermore, rising collaboration activities by key players are expected to drive growth of the global stem cell therapy market.
  • Under this collaboration, AstraZeneca utilized Procella Therapeutics' stem cell technology for the development of stem cell therapies in cardiovascular diseases.

Torrance Stem Cell Infusion and Peptide Therapy Launched By Springs Rejuvenation

Retrieved on: 
Thursday, November 17, 2022
Rejuvenation, Libido, Injury, Laboratory, Clinical professor, Cell, Bone marrow, Degenerative disease, Brain, Life, Physician, Regenerative medicine, Patient, Exosome, Heart nanotechnology, Mesenchymal stem cell, Pain management, Health, Muscle, Memory, NAD, Umbilical cord, B cell, Spring, FDA, Mayo Clinic, Medical imaging, Medical device

Springs Rejuvenation, a Torrance, CA-based health clinic (404-780-5617) specializing in regenerative medicine, announces an expansion of its anti-aging stem cell treatments.

Key Points: 
  • Springs Rejuvenation's anti-aging stem cell services can help to stimulate collagen production, increase muscle mass, and improve cognitive performance.
  • The company's website describes stem cells used in the new treatment as the 'blank slates' of the cell world.
  • - an expert in stem cell and medical aesthetics - Springs Rejuvenation has been offering regenerative medicine solutions to patients since its inception in 2019.
  • Dr. Charles A Pereyra, founder of Springs Rejuvenation, says, "Our purpose at Springs Rejuvenation is to assist you in feeling your best.

Global Mesenchymal Stem Cells (MSC) Advances and Applications Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
AIDS, Health, Safety, Research, Gene, Gene editing, Seminal vesicles, Ageing, Regenerative medicine, Population, Conditional sentence, Stem cell, Google Trends, Chondrocyte, Prevalence, Company, Exosome, Microsoft, Attention, MSC, B cell, Mesenchymal stem cell, Osteoblast, EVS, Geography, Adipocyte, Growth, Patient, Silk, Pharmaceutical industry

The "Mesenchymal Stem Cells - Advances and Applications, 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mesenchymal Stem Cells - Advances and Applications, 2022" report has been added to ResearchAndMarkets.com's offering.
  • It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.
  • With the competitive nature of this global market, you do not have the time to do the research.
  • Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes.

Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis

Retrieved on: 
Tuesday, March 8, 2022
Health, Stem Cells, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, Industry, B cell, Mesenchymal stem cell, Therapy, Stem cell, Hope, FDA, CRP, LLC, Tissue, American College, RA, Patient, Population, Regeneration, Disease, Cartilage, Arthralgia, Adult, C-reactive protein, Pharmaceutical industry

Fifteen patients received a single intravenous infusion of 200 million adipose-derived mesenchymal stem cells cultured by Hope Biosciences, also known as HB-adMSCs.

Key Points: 
  • Fifteen patients received a single intravenous infusion of 200 million adipose-derived mesenchymal stem cells cultured by Hope Biosciences, also known as HB-adMSCs.
  • We also wanted to demonstrate that our investigational drug can produce consistent results in patients with diverse medical backgrounds.
  • Hope Biosciences is currently in planning stages for a Phase IIb/IIIa randomized, placebo-controlled trial in RA.
  • Stem cells cultured at Hope Biosciences, LLC are currently studied in dozens of FDA-authorized studies for more than 20 disease and injury conditions.

Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel Corona Virus Infection (COVID-19)

Retrieved on: 
Tuesday, October 26, 2021
Exosome, Research, IV, Proning, Placenta, Patient, CGMP, FDA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AATB, Oxidative stress, Mesenchymal stem cell, Umbilical cord, COVID-19, Inflammation, IND, Stem cell, Development, Pharmaceutical industry

This marks the very first time the FDA has approved an IND that uses both of these components together and so first of its kind therapy.

Key Points: 
  • This marks the very first time the FDA has approved an IND that uses both of these components together and so first of its kind therapy.
  • This Phase II study will evaluate the utility of intravenous umbilical cord mesenchymal stem cells and exosomes in mitigating the pulmonary consequences of COVID-19.
  • Mesenchymal Stem Cells and their exosomes have unique therapeutic benefits, and together they create advanced therapeutic properties.
  • Vitti Labs' research and development division focuses on understanding various disease models and utilizing umbilical cord and placental derived Mesenchymal Stem Cells and Exosomes for therapies of those diseases.

Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

Retrieved on: 
Thursday, September 2, 2021
Annual report, U.S. Securities and Exchange Commission, SAN, Trigeminal neuralgia, Forward-looking statement, PSC, Risk, Private Securities Litigation Reform Act, Sciatica, Patient, Microsoft, RTX, ARD, Mesenchymal stem cell, Safety, Autoimmune disease, TRPV1, GLOBE, MSC, Osteoarthritis, Vaccine, Cancer, Therapy, Trial of the century, Antibody, Security (finance), Pain, FDA, CEO, Phase II, Pharmaceutical industry, Generic drug

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announcedtodaythe start of enrollment in itsPhase 2efficacy study ofhumanallogeneicadipose-derivedmesenchymal stemcells(COVI-MSC)forpatients suffering from COVID-19-induced acute respiratory distress (ARD)oracute respiratory distress syndrome (ARDS) in Brazil.

Key Points: 
  • SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announcedtodaythe start of enrollment in itsPhase 2efficacy study ofhumanallogeneicadipose-derivedmesenchymal stemcells(COVI-MSC)forpatients suffering from COVID-19-induced acute respiratory distress (ARD)oracute respiratory distress syndrome (ARDS) in Brazil.
  • The primaryobjectiveof this study is to evaluate the efficacy of COVI-MSCsin patients with COVID-19-induced ARDor ARDS.
  • Additionally, Sorrento will soon begin enrollment for two additional Phase 2 studies with COVI-MSC:
    A parallel Phase 2 placebo-controlled Phase 2 safety study to be conducted across multiple sites inthe United States.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Retrieved on: 
Tuesday, July 27, 2021
Research, FDA, Clinical trials, Philanthropy, Stem cells, Biotechnology, General Health, Health, Foundation, Science, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Mesenchymal stem cell, Adult stem cell, Stem-cell therapy, Shimon Slavin

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Mesenchymal stem cell, Adult stem cell, Induced stem cells, Shimon Slavin

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

Stimulating blood vessel formation with magnets

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Angiology, Stem cells, Growth factors, Vascular endothelial growth factor, Biotechnology, Endothelium, Stromal cell, Mesenchymal stem cell, Cell therapy, Craniofacial regeneration

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Life sciences, Stem cells, Stem-cell therapy, Mesenchymal stem cell, Amniotic fluid, Biocell Center

LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.

Key Points: 
  • LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.
  • The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid.
  • Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022.
  • With the proceeds from the IPO, Amniotics has the financial resources required to move our lead candidate PulmoStem into clinical development.